Brief: Medicenna Announces FDA Clearance Of Ind To Expand The Phase 1/2 Ability Study Of Mdna11 To The United States

Medicenna Therapeutics

27/10/2021 13:03

Oct 27 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA ANNOUNCES FDA CLEARANCE OF IND TO EXPAND THE
PHASE 1/2
ABILITY STUDY OF MDNA11 TO THE UNITED STATES
    * MEDICENNA THERAPEUTICS CORP - PRELIMINARY UPDATE ON
SAFETY,
PK/PD, AND BIOMARKER DATA EXPECTED BY YEAR-END 2021
    * MEDICENNA THERAPEUTICS CORP - INITIAL EFFICACY DATA UPDATE
FROM
ABILITY STUDY OF MDNA11EXPECTED IN MID-2022

Source text for Eikon:  ID:nGNXR7Hzg 
Further company coverage:  MDNA.TO